Oral Complications in Immunocompromised Patients: The Oncology Prototype
Douglas E. Peterson, DMD, PhD, FDS RCSEdSaturday, February 8
11:00 am - 11:45 am
Oral complications in immunocompromised patients can result in clinically impactful sequelae, including compromised quality of life as well as decreased patient survival in select cases. In addition, the oral lesions can be expensive to manage, resulting in increased use of typically limited health care resources. This presentation will address the state-of-the-science of this field, focusing on the myelosuppressed oncology patient as the prototype. Evidence-based strategies for prevention and management of oral disease caused by high-dose as well as emerging molecularly targeted cancer therapies will be discussed. Acute toxicities, including oral mucosal injury, pain, and infection, will be emphasized in relation to the complex interface of the oral cavity with overall systemic status. The presentation will highlight novel basic, translational, and clinical research that could lead to transformational strategies for oncology patient management in the future. The discussion will also compare and contrast the cancer patient prototype with other relevant models of immunocompromised patients, including those with AIDS.